Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report

By afschroeder • October 24, 2025

Le X, Baik C, Cho BC, Riess JW, Piotrowska Z, Johannes de Langen A, Goldberg SB, Goldman JW, Reguart N, Shiraishi Y, Ambrose H, Fraenkel PG, Ruiz BM, Smith PE, Tang KH, Yu HA. Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report. J Thorac Oncol. 2025 Oct 21:S1556-0864(25)02856-4. doi: 10.1016/j.jtho.2025.10.009. Epub ahead of print. PMID: 41130408.

Tags: Cardiology/Epi, EGFR, MET (min 3), NSCLC, Osimertinib, Publications, Savolitinib (max 5)

Related Posts

Pregnancy damps thermoregulatory rhythms across timescales through neural estrogen signaling in mice

Cortes LR, Xiong L, Vree AR, Reis FMCV, Kim N, Feng B, Hansen MR, Rashid S, Sandoval NP, Lopez JI, He Y, Adhikari A, van[...]

MAGGIC and PREDICT-HF Models in the VICTOR Trial: Do Traditional Risk Scores Still Work in Well-Treated Ambulatory Patients with HFrEF?

Senni M, Butler J, Cyr D, Anstrom KJ, Barash I, Bonaca MP, Budoff M, Cho MC, Crespo-Leiro MG, Corda S, Ezekowitz J, Lam CSP, Lewis[...]

Artificial intelligence-derived splenic response in cardiac positron emission tomography is associated with major adverse cardiovascular events: a multi-site study

Ramirez G, Dharmavaram NL, Shanbhag A, Miller RJH, Kavanagh PB, Yi J, Lemley M, Builoff V, Marcinkiewicz A, Dey D, Hainer J, Wopperer S, Knight[...]